


New generation DES providing synergy of Biodegradable Polymer with microporous surface to enhance optimal performance



Less Polymeric Load Compared To Other DES

- One million pores per cm² with average depth of 2 μm ensures optimum drug release with minimal use of polymer
- Shellac Resin (Wax-Free) ensures better polymer-drug binding with negligible polymer flaking during stent expansion
- Drug and polymer are co-released in 6-9 months leaving behind bare metal stent surface

Better Endothelialisation & Superior Strut Coverage

- Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue
- No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

Yukon Choice PC[®]
Sirolimus Eluting Coronary Stent System

PRODUCT MATRIX / ORDERING INFORMATION*

Stent Ø [mm]	Stent length [mm] & Article number											
Ø 2.00	YCPC2008	YCPC2012	YCPC2016	YCPC2018	YCPC2021	YCPC2024	YCPC2028	YCPC2032				
Ø 2.25	YCPC2208	YCPC2212	YCPC2216	YCPC2218	YCPC2221	YCPC2224	YCPC2228	YCPC2232				
Ø 2.50	YCPC2508	YCPC2512	YCPC2516	YCPC2518	YCPC2521	YCPC2524	YCPC2528	YCPC2532				
Stent Ø [mm]	Stent length [mm] & Article number											
Ø 2.75	YCPC2708	YCPC2712	YCPC2716	YCPC2718	YCPC2721	YCPC2724	YCPC2728	YCPC2732	YCPC2736	YCPC2740	YCPC2744	YCPC2748
Ø 3.00	YCPC3008	YCPC3012	YCPC3016	YCPC3018	YCPC3021	YCPC3024	YCPC3028	YCPC3032	YCPC3036	YCPC3040	YCPC3044	YCPC3048
Ø 3.50	YCPC3508	YCPC3512	YCPC3516	YCPC3518	YCPC3521	YCPC3524	YCPC3528	YCPC3532	YCPC3536	YCPC3540	YCPC3544	YCPC3548
Ø 4.00	YCPC4008	YCPC4012	YCPC4016	YCPC4018	YCPC4021	YCPC4024	YCPC4028	YCPC4032	YCPC4036	YCPC4040	YCPC4044	YCPC4048

* Please contact our Customer Care for available sizes #Sizes not CE Approved

COMPLIANCE CHART

Balloon Ø [mm]	Inflation pressure (bar / 10 ⁵ Pa)														
	NP					RBP									
	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Ø 2.00	1.90	1.94	1.97	2.00	2.03	2.07	2.10	2.13	2.17	2.20	2.23	2.27	2.35	2.38	2.41
Ø 2.25	2.15	2.18	2.21	2.25	2.28	2.32	2.35	2.38	2.42	2.45	2.49	2.52	2.55	2.59	2.62
Ø 2.50	2.40	2.43	2.47	2.50	2.54	2.57	2.60	2.64	2.67	2.71	2.74	2.77	2.81	2.84	2.88
Ø 2.75	2.65	2.68	2.72	2.75	2.78	2.82	2.88	2.81	2.92	2.95	2.98	3.01	3.28	3.31	3.34
Ø 3.00	2.89	2.93	2.97	3.00	3.04	3.08	3.15	3.07	3.19	3.23	3.26	3.30	3.34	3.37	3.41
Ø 3.50	3.37	3.42	3.46	3.50	3.54	3.58	3.67	3.59	3.71	3.75	3.79	3.84	3.88	3.92	3.96
Ø 4.00	3.85	3.90	3.95	4.00	4.05	4.10	4.21	4.11	4.26	4.31	4.36	4.41	4.46	4.51	4.56

TECHNICAL DATA

Medical Stainless Steel, 316 LVM, Surface containing micro-pores

Crossing Profile	0.035" / 0.89 mm	Entry Profile	0.016" / 0.41 mm
Strut Thickness	0.0034" / 87 μm	Proximal Shaft Diameter	1.9 F
Metallic Surface Area	13-19% depending on size	Distal Shaft Diameter	2.7 F
No Foreshortening		Recommended Guide Wire	0.014"
Balloon Marker Material	Platinum / Iridium	Guiding Catheter	min. 5 F



Manufactured By:
Translumina Therapeutics LLP
Plot No. 12, Pharmacy, Selaqui, Dehradun 248 197 (Uttarakhand) India
Drug Manufacturing License No. 12/UA/SC/P-2016

Registered Office:
Translumina Therapeutics LLP
Ground Floor, Metro Tower, LSC MOR Land, New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With:
Translumina GmbH
Neue Rottenburger Strasse 50, D-72379 Hechingen, Germany



CMC Medical Devices & Drugs S.L.
C/HoracioLengo N° 18, CP 29006, Málaga - Spain. Tel: +34951214054
Email: mmateos@cmcmedicaldevices.com | web: www.cmcmedicaldevices.com

Customer Care No: +91 11-2874 2874
Email: info@translumina.in
Web: www.translumina.in for more details.

Yukon Choice PC is a registered trademark of Translumina Therapeutics LLP

Please refer to the Instructions for Use supplied with these devices for indications, contraindications, Adverse Events, suggested procedures, warnings and precautions.

Doc.Ref.No.YCPC-EC Issue01, Revision 06



Yukon Choice PC[®]
Sirolimus Eluting Coronary Stent System

Heartfelt trust lasts a lifetime.

Yukon Choice PC[®]

Sirolimus Eluting Coronary Stent System

World's Longest Studied Drug Eluting Stent

▶ 2004 CATHERIZATION
CARDIOVASCULAR INTERVENTIONS
89:367-374 (2017)

At 2 years, microporous surface was found to be equally safe as compared to electropolished surface. Rough surfaces showed lesser restenosis rates.

▶ 2008 Biomaterials

In Pre-clinical trial, it was seen that Yukon Choice PC with microporous surface reduced the amount of polymeric load to 1/4th and is assured with consistent kinetics & low inflammation.

▶ 2011 JACC
Journal of the American College of Cardiology

At 3 years, Yukon Choice PC proved equivalence to Xience in terms of Late loss, TLR and Primary Composite MACE.

▶ 2012 European
Society of
Cardiology **European
Heart Journal**

At four years follow up, Yukon Choice PC shows reduction of risk by 50% in Definite Stent Thrombosis & by 78% in Very Late stent thrombosis as compared to the first generation DES with similar efficacy.

▶ 2013 International Journal of
CARDIOLOGY

At four years follow up, Yukon Choice PC demonstrated reduced rates in stent thrombosis in patients with diabetes mellitus as compared to durable polymer.

▶ 2014 EuroIntervention

Yukon Choice PC showed equivalent efficacy & better safety in terms of stent thrombosis compared to Xience & Cypher at 5 years follow up.

▶ 2018 ESC
European Society
of Cardiology

Yukon Choice PC is recommended by ESC guidelines 2018 on the basis of large randomized trials where primary end points were achieved.



▶ 2018 Circulation
Journal of the American Heart Association

At 10 years, Yukon Choice PC showed equivalence in terms of MACE rate, Mortality and TLR rate compared to Xience and a superiority over Cypher for the same outcomes.

Yukon Choice PC showed the lowest rate of definite or probable stent thrombosis with a significant risk reduction than the Cypher stent (50% reduction) and a numerically lower rate as than the 'Xience' stent (29% reduction).

